Algorae Pharmaceuticals Limited (ASX:1AI)

Market Cap	25.32M +150.1%
Revenue (ttm)	n/a
Net Income	-1.01M
EPS	-0.00
Shares Out	2.03B
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	9,735
Open	0.0120
Previous Close	0.0125
Day's Range	0.0120 - 0.0120
52-Week Range	0.0050 - 0.0240
Beta	-0.06
Analysts	n/a
Price Target	n/a
Earnings Date	May 7, 2026

About Algorae Pharmaceuticals

Algorae Pharmaceuticals Limited, a pharmaceutical development company, engages in the research and development of living cells technologies primarily in New Zealand. The company’s product pipeline includes AI-116, a novel combination drug candidate made up of donepezil and cannabidiol for the treatment of dementia, including Alzheimer’s disease; AI-168, a novel combination drug candidate made up of a cannabinoid and an off-patent pharmaceutical ingredient for the treatment of cardiovascular disease, such as hypertension; and NTCELL, an alginate...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1987
• Employees: 48
• Stock Exchange: Australian Securities Exchange
• Ticker Symbol: 1AI

Financial Performance

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Jul 15, 2026

Data Sources Report a data error